Is Rhythm Pharmaceuticals, Inc. (RYTM) a Buy, Sell, or Hold?
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$109.55 USD
-$0.41 (-0.37%)
- Volume
- 202.42K
- Average Volume
- 808.67K
- Market Capitalization
- $7.51B
- P/E Ratio
- -35.00
- Dividend Yield
- 0.00%
- Price Target
- $141.00
- Year High
- $122.20
- Year Low
- $74.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.17
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David Meeker |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RYTM |
| CUSIP | 76243J105 |
| CIK | 0001649904 |
| Web | https://www.rhythmtx.com |
| Phone | 857 264 4280 |
| Currency | USD |
| Employees | 414 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.85 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.17 |
| Quick Ratio | 3.89 |
| Cash Ratio | 0.60 |
Sales & Book Value
| Annual Sales | $189.76M |
| Price / Sales | 34.60 |
| Cash Flow | -1.77 |
| Price / Cash Flow | -62.38 |
| Price / Book | 60.59 |
Price Target and Rating
| Average Stock Price Forecast | $141.00 |
| High Stock Price Forecast | $155.00 |
| Low Stock Price Forecast | $125.00 |
| Forecast Upside/Downside | -22.30% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 20 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.11 |
| Trailing P/E Ratio | -35.00 |
| PEG Ratio | 2.87 |
| P/E Growth | 2.87 |
| Net Income | $-196.54M |
| Net Margin | -93.33% |
| Pretax Margin | -92.89% |
| Return on Equity | -203.25% |
| Return on Assets | -45.82% |
Financials Score
| AltmanZ Score | 9.42 |
| Piotroski Score | 3.00 |
| Working Capital | 326.89M |
| Total Assets | 442.32M |
| Ebit | -181.96M |
| Market Cap | 7.37B |
| Total Liabilities | 319.41M |
Poll Results
About Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, includi ... ng obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
2026-07-08 17:07:00
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
2026-06-17 12:02:18
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity
2026-06-16 11:50:37
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years. Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon therapy achieved progressive reductions in body mass index and hunger measures in patients with acquired hypothalamic obesity at one year.
2026-06-15 16:01:00
BOSTON, June 15, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced new data from multiple presentations during the Endocrine Society's Annual Meeting (ENDO 2026) in Chicago.
Why Is Rhythm Pharma Stock Jumping Today?
2026-06-15 12:51:46
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock is trading higher on Monday after the company reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
2026-06-13 08:01:00
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --
2026-06-12 16:01:00
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
2026-06-08 17:28:31
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Rhythm Pharmaceuticals, Inc. (RYTM) stock price?
-
Rhythm Pharmaceuticals, Inc.(NASDAQ:RYTM) stock price is $109.55 in the last trading session. During the trading session, RYTM stock reached the peak price of $122.2 while $74.5 was the lowest point it dropped to. The percentage change in RYTM stock occurred in the recent session was --0.37% while the dollar amount for the price change in RYTM stock was -$-0.41.
-
RYTM's industry and sector of operation?
-
The NASDAQ listed RYTM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RYTM?
-
Hunter C. Smith | Chief Financial Officer & Treasurer
Joseph Shulman | Chief Technical Officer
Yann Mazabraud | Executive Vice President & Head of International
Sarah Ryan | Vice President of Sales & Marketing
Jim Flaherty | Senior Vice President & General Counsel -
How many employees does RYTM have?
-
Number of RYTM employees currently stands at 414. RYTM operates from 222 Berkeley Street, Boston, MA 02116, US.
-
Link for RYTM official website?
-
Official Website of RYTM is: https://www.rhythmtx.com
-
How do I contact RYTM?
-
RYTM could be contacted at phone #857 264 4280 and can also be accessed through its website. RYTM operates from 222 Berkeley Street, Boston, MA 02116, US.
-
How many shares of RYTM are traded daily?
-
The average number of RYTM shares traded daily for last 3 months was 808.67K.
-
What is the market cap of RYTM currently?
-
The market value of RYTM currently stands at $7.51B with its latest stock price at $109.55